AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06764355
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg, 1h-IVF, Q3W on day 1 for 2 cycles
Trial: NCT06764355
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2, 3h-IVF, Q3W on day 1 for 2 cycles
Trial: NCT06764355
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2, 2h-IVF, Q3W on day 1 for 2 cycles
Trial: NCT06762743
Drug: Brivaracetam Oral Solution (Test Formulation)
RxNorm normalized name: brivaracetam Oral Solution
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The drug is manufactured by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.
Trial: NCT06762743
Drug: Brivaracetam Oral Solution (Reference Formulation)
RxNorm normalized name: brivaracetam Oral Solution
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The drug is manufactured by UCB Pharma S.A. under the trade name Briviact®. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.
Trial: NCT06768411
Drug: PEG-rhGH
RxNorm normalized name: RhGH-PEG
DrugBank: Lonapegsomatropin (DB16220)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1= 0.2mg/kg/week Initial doses of PEG-rhGH 2=0.22mg/kg/week Initial doses of PEG-rhGH
Trial: NCT06768411
Drug: GnRHa
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. pubertal children of short stature without GnRHa treatment~2. pubertal children of short stature with GnRHa treatment
Trial: NCT06427798
Drug: 68Ga-DOTATATE
RxNorm normalized name: 68Ga-DOTATATE
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga-DOTATATE PET/CT whole-body scanning will be done at target dose of 5 mCi. The whole-body PET/CT scan will be started approximately 60 minutes after the tracer injection and will take up to 2 hours.
Trial: NCT04550377
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The drug product to be used in this study is an oral formulation of CBD
Trial: NCT06772974
Drug: Doxylamine Succinate USP
RxNorm normalized name: Doxylamine Succinate
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tab. Doxylamine Succinate
Trial: NCT05844982
Drug: Faricimab
RxNorm normalized name: Faricimab
DrugBank: Faricimab (DB15303)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6.0 mg intravitreal injection at randomization and every 3 months
Trial: NCT05844982
Drug: fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.19 mg fluocinolone acetonide intravitreal implant (Iluvien) at randomization and at 24 months
Trial: NCT06511726
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy and immunotherapy: Cadonilimab + cisplatin + albumin-bound paclitaxel, for a total of 2 cycles (cisplatin 75 mg/m² + albumin-bound paclitaxel 260 mg/m² q3w, Cadonilimab 10 mg/kg q3w).
Trial: NCT06773195
Drug: Ulixertinib
RxNorm normalized name: Ulixertinib
DrugBank: Ulixertinib (DB13930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There are 3 planned dose levels of ulixertinib(450 mg BID, 300 mg BID, or 150 mg BID)
Trial: NCT06773195
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib for 28 day cycles.
Trial: NCT06752525
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive SPGB block with 2 ml volume on each side (1.5 mL of bupivacaine 0.5% + 0.5 mL of magnesium sulphate 10%).
Trial: NCT06752525
Drug: Magnesium Sulphate 500 mg
RxNorm normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive SPGB block with 2 ml volume on each side (1.5 ml bupivacaine 0.5% plus 0.5 ml saline).
Trial: NCT06756139
Drug: Flupentixol and Melitracen Tablets
RxNorm normalized name: melitracen
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients take Flupentixol and Melitracen Tablets
Trial: NCT06751849
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
Trial: NCT06751849
Drug: Neoantigen-loaded DC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Trial: NCT06780345
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanically ventilated neonates will receive the usual protocol of sepsis plus vitamin C with a loading dose of 0.5 gm /kg and a maintenance dose of 0.5 gm /kg/hour adjusted for six hours for 7-10 days.
Trial: NCT06773091
Drug: Fludarabine (FLU)
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (FLU) is administered as a lymphodepletion regimen prior to NK042 infusion.
Trial: NCT06465576
Drug: Solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins.
Trial: NCT06465576
Drug: Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins.
Trial: NCT06465576
Drug: Solifenacin + Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins.
Trial: NCT05720065
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Randomized double-blind administration
Trial: NCT05170399
Drug: PREVNAR 20
RxNorm normalized name: Prevnar 20
DrugBank: Streptococcus pneumoniae type 4 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
Trial: NCT05850832
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery.
Trial: NCT05850832
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
Trial: NCT06162377
Drug: Methylnaltrexone
RxNorm normalized name: Methylnaltrexone
DrugBank: Methylnaltrexone (DB06800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by SC (injection)
Trial: NCT05540574
Drug: Zolpidem
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg (and up to10mg) Diphenhydramine given orally
Trial: NCT06680830
Drug: NEU-411
RxNorm normalized name: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP
DrugBank: Zanidatamab (DB15471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEU-411, a potent, selective, orally bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity
Trial: NCT06692673
Drug: Use of Linaclotide as a single agent Colonoscopy prep
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: We plan to conduct a pilot study to determine the feasibility of a quality bowel preparation with two 290mg doses of Linaclotide (first dose given 36 hours before, and the other 8 hours prior to the procedure) along with 2 Liters of Gatorade (to prevent dehydration) given the day prior to the colonoscopy instead of the current standard 4 liters of PEG regimen. All study participants will be asked to consume a clear liquid diet for 24hours before the procedure.
Trial: NCT05275686
Drug: Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray
RxNorm normalized name: Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will use two sprays in each nostril twice a day for 6 weeks and additional 6 weeks (open label).
Trial: NCT05447208
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone is supplemented before and during the ovarian stimulation till the day of oocyte retrieval
Trial: NCT06479161
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.95 grams oral
Trial: NCT05447208
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
Trial: NCT05162352
Drug: Donafenib+sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 (Safety Run-in): donafenib 200mg P.O. BID and sintilimab 200mg I.V. for a 21-days cycle.~Part 2: donafenib at the recommended phase 2 dose determined from Part 1 and sintilimab 200mg I.V. Q3W.~Donafenib will last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Sintilimab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Patients will be allowed to have donafenib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
Trial: NCT06466798
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab infusions will be given intraventricularly once every other week for 12 weeks. Dosing will be based upon patient body weight.
Trial: NCT06466798
Drug: 5-Azacytidine
RxNorm normalized name: 5-azacytidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg 5-Azacytidine infusions will be given intraventricularly once weekly for twelve consecutive weeks.
Trial: NCT05904080
Drug: Cabozantinib S-malate
RxNorm normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06088004
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 antibody
Trial: NCT05401110
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib given by mouth daily at 40mg or 80mg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
Trial: NCT05401110
Drug: Carotuximab
RxNorm normalized name: Carotuximab
DrugBank: Carotuximab (DB06322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotuximab is administered intravenously weekly for the first 4 weeks, then every 2 weeks at 10mg/kg or 15 mg/kg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
Trial: NCT06302140
Drug: Nanatinostat (free base) tablets in combination with Valganciclovir
RxNorm normalized name: valganciclovir Oral Tablet
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment A: a single, oral dose of nanatinostat (free base) tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
Trial: NCT06302140
Drug: Nanatinostat mesylate tablets in combination with Valganciclovir
RxNorm normalized name: valganciclovir Oral Tablet
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment B: a single, oral dose of nanatinostat mesylate tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
Trial: NCT06302140
Drug: Single-agent Nanatinostat (free base) tablets
RxNorm normalized name: Panobinostat
DrugBank: Nanatinostat (DB15419)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 40 mg once daily under fed conditions until disease progression or unacceptable toxicity, whichever occurs first.
Trial: NCT05917860
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degarelix is injected subcutaneously into the fatty tissue of the abdomen. A typical protocol consists of a starting dose of 240 mg with a maintenance dose of 80 mg administered every 28 days. In this study, one starting dose and two maintenance doses of Degarelix will be administered between baseline and TULSA treatment in accordance with the terms of Degarelix marketing authorizations.
Trial: NCT06137638
Drug: ENA-001
RxNorm normalized name: ENA-001
DrugBank: ENA-001 (DB18153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENA-001 will be prepared in Ringer's lactate solution. A loading dose will be administered for 20 minutes followed by continuous infusion until the patient meets the criteria for PACU discharge (≥ 9 Aldrete score) or ABG reveals PaCO2 \< 30 mmHg with pH in the normal range. ENA-001 is for IV injection ready for use per subject by the investigational pharmacy, according to the randomization schedule.
Trial: NCT06619600
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10 mg qd
Trial: NCT06512051
Drug: SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: SHR-A2102~Drug: Adebrelimab~Drug: Cisplatin/ Carboplatin
Trial: NCT05163366
Drug: GROUP A
RxNorm normalized name: Blood group A IgM
DrugBank: Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen (DB10798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal Ketamine will be administered at 6 mg/kg and with a rectal nozzle it's infused through the rectum. The rectal ketamine will be administered after scoring pain just before the start of the procedure and then about 15 minutes later the procedure will start when the patient has achieved a nystagmus.
Trial: NCT05163366
Drug: GROUP B
RxNorm normalized name: Blood group B IgM
DrugBank: Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen (DB10284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The tradition standard protocols involve the use of 0.3mg/kg of oral morphine about an hour before the start of the procedure before the start of the procedure to allow for the onset of action of oral morphine for every single procedure in this arm.
Trial: NCT04756687
Drug: Dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT05761860
Drug: OxyCODONE 5 mg Oral Tablet
RxNorm normalized name: oxyCODONE 5 mg oral tablet
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone 5mg oral administration
Trial: NCT05761860
Drug: OxyCODONE 2.5 mg Oral Tablet
RxNorm normalized name: ASA 325 MG / Oxycodone 2.5 MG Oral Tablet
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone 2.5mg oral administration
Trial: NCT05761860
Drug: Oxytocin Nasal Spray (48 IU)
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin administration (48 IU)
Trial: NCT04819269
Drug: Tivanisiran sodium ophthalmic solution
RxNorm normalized name: sodium chloride Ophthalmic Ointment
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop in the affected eye(s) once daily
Trial: NCT04819269
Drug: Vehicle ophthalmic solution
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in the affected eye(s) once daily
Trial: NCT05847257
Drug: Letrozole tablets
RxNorm normalized name: Letrozole Tablets
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: letrozole 2.5mg twice weekly for 3 months
Trial: NCT05357989
Drug: buntanetap/posiphen
DrugBank: Posiphen (DB15317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMC (vegetarian source) capsule shells
Trial: NCT03984565
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: High-CBD, low-THC sublingual product formulated in palm oil
Trial: NCT05564650
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05564650
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05694715
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given orally
Trial: NCT05694715
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously (IV)
Trial: NCT05714072
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg BID or 15mg BID
Trial: NCT05714072
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50, 100 and 150 mg
Trial: NCT06073132
Drug: AC-203
RxNorm normalized name: ODM-203
DrugBank: ODM-203 (DB16843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product is formulated as 1% topical ointment
Trial: NCT05789043
Drug: camrelizumab+apatinib+TMZ
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: camrelizumab 200mg，q2w+apatinib 250mg，qd+TMZ 200mg/m2，day1-5/28
Trial: NCT05789043
Drug: camrelizumab+apatinib
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: camrelizumab 200mg，q2w+apatinib 250mg qd
Trial: NCT05789043
Drug: camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: camrelizumab 200mg，q2w
Trial: NCT06318273
Drug: ABBV-969
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT06043427
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m²
Trial: NCT06043427
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg/kg
Trial: NCT06043427
Drug: Zanidatamab
RxNorm normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose and schedule to be assigned at enrollment
Trial: NCT05730036
Drug: Linvoseltamab
RxNorm normalized name: Linvoseltamab
DrugBank: Linvoseltamab (DB17447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN5458 will be administered by intravenous (IV) infusion